CervoMed reports Q2 2026 results, seeks partner for neflamapimod Phase 3 in DLB
The company disclosed new AAIC data supporting a 50 mg dose, an ILAP designation in the UK, and cash runway into the third quarter of 2027.
SEC filing
Latest
5 stories
Thursday, September 10
Thursday, September 3
CervoMed/EIP Pharma trial posts results for neflamapimod in Lewy body dementia
Monday, August 10
Tuesday, August 4
CervoMed's neflamapimod gets UK Innovation Passport for Lewy body dementia
The designation gives CervoMed early, coordinated access to UK regulatory, health system, and reimbursement bodies as it seeks a partner for a planned Phase 3 trial.
SEC filing
Tuesday, July 14
CervoMed presents new neflamapimod data at AAIC, backs 50 mg dose for DLB Phase 3
New biomarker, imaging and dosing analyses from the Phase 2b RewinD-LB trial support a 50 mg three-times-daily dose for a planned Phase 3 study in dementia with Lewy bodies.
SEC filing (2)